Public Release: 

Study finds mechanisms of early insulin treatment for diabetes may produce better outcomes

Three months of intensive insulin therapy equal to 15 months of intensive oral therapy and may protect insulin-producing beta cells

American Osteopathic Association

A pilot study of 23 adults with newly diagnosed type 2 diabetes found early insulin therapy to be as effective as 15 months of oral therapy and may improve the body's ability to produce insulin.

The current standard of care calls for initial treatment with oral therapies that suppress glucose production by the liver. In contrast, insulin is a hormone produced by the pancreas that allows the body to use glucose and prevents blood sugar levels from getting too high. If used early it can provide effective treatment with fewer metabolic side effects.

Researchers from Ohio University and Western University of Health Sciences College of Osteopathic Medicine will present their updated findings at OMED 15 October 17 in Orlando. The pilot study was conducted after successful cases series that were completed at The Ohio University Diabetes Institute.

In the randomized controlled trial, the insulin-treated group's A1C levels decreased from 10.1 percent to 6.7 percent after 15 months. The group receiving intensive oral therapy saw its A1C level drop from 9.9 percent to 6.8 percent at 15 months. The insulin treatment was well tolerated with no severe hypoglycemia. While the intensive oral therapy group gained weight, insulin-treated subjects lost an average of five pounds.

"While the improvement in glucose was relatively comparable between the two groups, our findings support the idea that the body can improve its natural insulin secreting ability when early insulin is given," said lead researcher Jay Shubrook, DO. "This may be because early insulin therapy protects beta cells in the pancreas that respond to glucose and produce insulin."

Based on additional research published in the journal Cell Metabolism in 2014, the mechanism appears to be re-differentiation of beta cells, Shubrook said.

Shubrook noted limitations to the study, including its size and the number of participants considered severely obese, with a body mass index (BMI) of 40 or greater. Despite the limitations, the study provides new clues to improving outcomes for patients newly diagnosed with type 2 diabetes.

###

About OMED 15

OMED 15 is a five-day event offering clinical and research updates in 15 specialties, with an emphasis on osteopathic principles and practices.

The osteopathic philosophy of medicine takes a whole person approach to prevention, diagnosis and treatment, giving its practitioners a distinct model for clinical problem solving and patient education. OMED welcomes all health care professionals-- including MDs, nurse practitioners and physician assistants--interested in osteopathic medicine's collaborative approach to increasingly complex medical issues.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.